A pooled analysis of 15 public studies gathering 1050 EGFR-mutated NSCLC patients showed that patients with EGFR mutations had decreased PD-L1 expression (odds ratio: 1.79, 95% CI: 1.10–2.93; p = 0.02) [71]. Here, EGFR is linked to non-small cell lung carcinoma.